logo-loader
RNS
Ananda Pharma Plc

Ananda Pharma PLC - Appointment of Chris Tovey, GW Pharma Former COO

RNS Number : 9881D
Ananda Pharma PLC
08 April 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

A logo with blue and green dots Description automatically generated

 8 April 2025

 

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

 

Appointment of Chris Tovey, GW Pharmaceuticals' Former COO

 

Ananda Pharma plc (AQSE: ANA), a UK-based biopharmaceutical company developing regulatory approved cannabinoid medicines to treat complex, chronic conditions, is very pleased to announce the appointment of Mr. Chris Tovey, ex-COO of GW Pharmaceuticals plc ("GW") and Jazz Pharmaceuticals plc ("Jazz"), as an advisor to the Company.

 

Highlights

·    GW achieved the first ever regulatory approval for a naturally derived cannabidiol medicine in the US, UK and Europe.

·    Chris was COO of GW Pharma when it was acquired by Jazz Pharmaceuticals for $7.2bn, globally the largest strategic cannabis exit to date

·    Post GW's acquisiton by Jazz, Chris was appointed COO of Jazz

·    Executive leader at GW through its NASDAQ IPO and subsequent significant capital raisings (>$1bn over 8 years)

·    Key executive who led the operational growth of GW, including commercial expansion, manufacturing, technology and staffing

·    To view the supporting video by Charles Morgan, Chairman of Ananda and to ask questions please go to our Hub:https://investors.anandapharma.co.uk/link/NPwkAP

·    Q&A webinar by CEO Melissa Sturgess to be held on Friday 11th April at 12.30p.m. BST: https://investors.anandapharma.co.uk/webinars/0y5Rxe-chris-tovey-appointment-q-a

Chris Tovey was a key member of the leadership team at GW Pharmaceuticals plc ("GW"), the world's first pharmaceutical company to pursue and successfully secure FDA, EMA and MHRA approval for a CBD medicine that is now approaching Blockbuster (more than $1bn of annual revenues) status. He joined GW as an Executive Board Director and COO in 2012, and played a critical role taking GW from its IPO on NASDAQ in 2013 through to its acquisition by Jazz Pharmaceuticals for $7.2 billion in 2021: the largest strategic exit transaction in the cannabinoid industry to date.

Given Mr. Tovey's prior experience he will help guide Ananda's corporate, operational, commercial and drug development programmes. Working closely with the Ananda Board and Senior Management, he will support the build-out of its best-in-class team to deliver a regulatory approved CBD based medicine to patients and the market. It is expected that Mr. Tovey will join Ananda's Board in due course. To align his interests with shareholders, a total of 50,000,000 options have been granted for  ordinary shares of £0.002 each in the capital of the Company ("Ordinary Shares") to Mr Tovey, subject to certain vesting and performance conditions, all with a 10-year life. The options have an exercise price of 0.44 pence, being the 7 day VWAP preceeding his appointment as a consultant. Conditional upon being appointed a director of the Company, Mr. Tovey would be granted options over up to a further 75,000,000 Ordinary Shares.

Ananda's Chairman and largest shareholder, Charles Morgan commented: "We are honoured to have Chris join Ananda. Securing his services allows us to benefit from his unique experience gaining the first-ever FDA and EMA approvals for a CBD medicine, and his input will help us achieve our ambition of getting a regulatory approved CBD medicine to market faster and at a lower cost than would otherwise be the case.  Mr. Tovey's senior level experience at GW will be invaluable and his commitment to Ananda is a vote of confidence in our approach and our team."

Chris Tovey commented: "It is my sincere belief that there is still much unfinished business for cannabinoid based medicines and Ananda is the only company I have come across that is approaching this opportunity properly.  I believe they are well placed to replicate what we did at GW, in different indications. The opportunities for significant revenues with regulatory approved cannabinoid medicines are huge and Ananda is well placed to create best-in-class products to make a significant difference for patients."

Melissa Sturgess, CEO, will give a live Q&A session about Chris joining Ananda via the Company's InvestorHub on 11th April 2025 at 12.30p.m. BST. The Q&A session is open to all existing and potential shareholders. Questions can be submitted pre-event via the webinar page up until 10th April 2025 at 5.00p.m. BST, or at any time during the live presentation.

 

Investors can sign up to the webinar for free via: https://investors.anandapharma.co.uk/webinars/0y5Rxe-chris-tovey-appointment-q-a

 

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

 

For more information, please visit our website:

 

To stay up to date with Ananda's news please follow our social media channels:  

  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

  

-Ends-

  

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA PHARMA PLC 

+44 (0)7463 686 497 


ir@anandapharma.co.uk

 

Chief Executive Officer 


Melissa Sturgess 




Finance Director 


Jeremy Sturgess-Smith 


VIRIDIAN CAPITAL ADVISORS (US)

Scott Greiper

+1 (646) 330-0704

sgreiper@viridianca.com

 

 


SP ANGEL CORPORATE FINANCE LLP 


 


Corporate Finance 

+44 (0)20 3470 0470 

Richard Morrison 


Josh Ray




Corporate Broking 

+44 (0)20 3470 0534

Abigail Wayne 

Abigail.wayne@spangel.co.uk

Rob Rees 

 

Rob.ress@spangel.co.uk



YELLOW JERSEY PR

Sarah MacLeod

Charles Goodwin

Zara McKinlay

+44 (0)20 3004 9512

ananda@yellowjerseypr.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXKZGGDKNZGKZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read